Abstract: A process for producing an eriocitrin-containing material comprises the steps of: preparing an eriocitrin-containing citrus extract from a citrus fruit using an extractant; and separating eriocitrin from the citrus extract. The step of separating eriocitrin from the citrus extract comprises the steps of: bringing the citrus extract into contact with a porous synthetic adsorption resin such that eriocitrin in the citrus extract is adsorbed on the porous synthetic adsorption resin, the porous synthetic adsorption resin comprising a phenol-formaldehyde resin as a main framework and having amino and phenolic hydroxyl groups; and eluting the eriocitrin adsorbed on the porous synthetic adsorption resin using an elution solvent.
Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Type:
Grant
Filed:
June 13, 2011
Date of Patent:
March 24, 2015
Assignee:
Theracos, Inc.
Inventors:
Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
Abstract: An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.
Type:
Grant
Filed:
November 24, 2008
Date of Patent:
March 3, 2015
Assignee:
Research Foundation of the City University of New York
Abstract: The invention provides the Zidovudine-conjugated quinoline compound N-((1-(2-(hydroxy-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8a-hexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide. The compound can selectively kill hepatoma cells, especially hepatoma cells with hepatitis B, and inhibit the growth of subcutaneous tumors in mice, but has no significant toxicity to normal liver cells. Experiments confirm that the compound has an anti-hepatoma effect and can be used in preparation of anti-hepatoma drugs.
Type:
Grant
Filed:
June 15, 2012
Date of Patent:
February 10, 2015
Assignee:
Huazhong University of Science and Technology
Abstract: The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in an animal comprising administering to said animal an effective amount of a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto.
Abstract: The invention relates to assays to detect selective gene regulation by ligand dependent transcription factors. The invention also relates to selective modulators of the glucocortocoid receptor for treatment of inflammation and allergic and immune-mediated diseases.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
January 27, 2015
Assignee:
The Regents of the University of California
Abstract: The present invention relates generally to the field of therapeutics and in particular, chemotherapy. Even more particularly, the present invention provides therapeutic strategies which reduce the toxicity or enhance the efficacy of chemotherapeutic agents. Compositions and methods of treatment and prophylaxis are also contemplated by the present invention.
Abstract: Compositions comprising NKT cell agonist compounds and a physiologically acceptable vehicle are provided. Methods of stimulating an NKT cell and enhancing an immune response are also disclosed. Further provided are vaccine preparations comprising NKT cell agonist compounds.
Type:
Grant
Filed:
August 4, 2010
Date of Patent:
January 13, 2015
Assignees:
The Scripps Research Institute, The University of Chicago, Brigham Young University
Inventors:
Luc Teyton, Albert Bendelac, Paul B. Savage
Abstract: A low-molecular-weight hyaluronic acid and/or its salt is obtained by dispersing hyaluronic acid and/or its salt in an acidic water-containing medium.
Abstract: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
Type:
Grant
Filed:
June 10, 2011
Date of Patent:
December 23, 2014
Assignee:
Novo Nordisk A/S
Inventors:
Shawn DeFrees, David A. Zopf, Caryn Lang Bowe
Abstract: A novel solvent-free method for the cationization of a legume starch, and uses of the cationic starches thus obtained, in aqueous compositions and the paper industry, including the folding carton or paper thus obtained.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
December 16, 2014
Assignee:
Roquette Freres
Inventors:
Marika Ladret, Edmond Dobrogoszcz, Hervé Gombert, Philippe Sabre
Abstract: The present invention provides composition comprising one or more glycosaminoglycan mimetics and uses thereof. The subject glycosaminoglycan mimetics are particularly useful for treatment of neuronal injuries including without limitation spinal cord injuries.
Abstract: The present process provides an improved method for the preparation of 4-amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydrofuran-2-yl)-1H-pyrimidin-2-one of the formula (IV) which is a potent inhibitor of Hepatitis C Virus (HCV) NS5B polymerase.
Type:
Grant
Filed:
October 5, 2007
Date of Patent:
December 16, 2014
Assignee:
Gilead Pharmasset LLC
Inventors:
Steven D. Axt, Keshab Sarma, Justin Vitale, Jiang Zhu, Bruce Ross, Suguna Rachakonda, Quingwu Jin, Byoung-Kwon Chun
Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
Type:
Grant
Filed:
May 22, 2007
Date of Patent:
November 11, 2014
Assignees:
New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New York
Inventors:
Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
Abstract: A composition comprising at least a compound (a) of general formula (I): and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1 to 1/1013. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the pests and diseases of crops and increasing their yield by using this composition.
Type:
Grant
Filed:
December 11, 2007
Date of Patent:
November 4, 2014
Assignee:
Bayer CropScience AG
Inventors:
Heike Hungenberg, Wolfgang Thielert, Jean-Pierre Vors
Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.
Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
Type:
Grant
Filed:
September 29, 2010
Date of Patent:
October 14, 2014
Assignees:
Baxter Healthcare S.A., Baxter International Inc.